Neurotech Secures Binding Commitments for-AU$4 Million Equity Placement to Advance NTI164 Program.
Neurotech International Limited (ASX: NTI) has received binding commitments totaling approximately AU$4 million through a Placement supported by existing and new institutional, professional, and sophisticated investors. The Placement involves the issue of 285.98 million new fully paid ordinary shares at AU$0.014 per share, representing a 23.8% discount to the 15-day VWAP of AU$0.0184. Subject to shareholder approval, all directors have elected to participate, contributing a combined ~AU$250,000, demonstrating strong alignment with shareholder interests.
Funds raised will be applied to advancing NTI164 through non-clinical toxicology and registration-enabling clinical programs, progressing regulatory submissions, and supporting general working capital. The majority of shares will be issued under the Company’s existing ASX Listing Rule 7.1 and 7.1A capacities, with the remainder subject to shareholder approval. Taylor Collison Limited acted as Lead Manager.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Neurotech Secures Binding Commitments for-AU$4 Million Equity Placement to Advance NTI164 Program.
Neurotech International Limited (ASX: NTI) has received binding commitments totaling approximately AU$4 million through a Placement supported by existing and new institutional, professional, and sophisticated investors. The Placement involves the issue of 285.98 million new fully paid ordinary shares at AU$0.014 per share, representing a 23.8% discount to the 15-day VWAP of AU$0.0184. Subject to shareholder approval, all directors have elected to participate, contributing a combined ~AU$250,000, demonstrating strong alignment with shareholder interests.
Funds raised will be applied to advancing NTI164 through non-clinical toxicology and registration-enabling clinical programs, progressing regulatory submissions, and supporting general working capital. The majority of shares will be issued under the Company’s existing ASX Listing Rule 7.1 and 7.1A capacities, with the remainder subject to shareholder approval. Taylor Collison Limited acted as Lead Manager.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au